logo
Twitter
Discord
Email
logo
Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc.

NASDAQ•ARCT
CEO: Mr. Joseph E. Payne M.Sc.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2013-05-22
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Contact Information
10628 Science Center Drive, Suite 250, San Diego, CA, 92121, United States
858-900-2660
arcturusrx.com
Market Cap
$174.42M
P/E (TTM)
-3.5
40.9
Dividend Yield
--
52W High
$24.17
52W Low
$5.85
52W Range
3%
Rank68Top 92.8%
1.7
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$17.15M-55.81%
4-Quarter Trend

EPS

-$0.49-450.00%
4-Quarter Trend

FCF

-$17.33M-27.31%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revenue Drops Post-Transition Total revenue $74.8M (9M 2025), down 42% from $129.5M, due to KOSTAIVE commercial shift.
Net Loss Significantly Reduced Nine-month net loss narrowed to $36.7M from $50.9M, reflecting lower operating expenses across R&D.
R&D Spending Decreases R&D expenses fell 42% to $87.7M for nine months, driven by lower manufacturing and clinical costs.
Strong Cash Balance Maintained Cash, equivalents, and restricted cash totaled $237.2M as of September 30, 2025, supporting operations.

Risk Factors

Material Weakness Persists Material weakness in ITGCs regarding user access and change management remains unresolved as of September 30, 2025.
Government Shutdown Risk Prolonged US federal shutdown starting October 2025 could delay SEC/FDA reviews, impacting operations and financing.
CSL Seqirus Separation Risk Potential separation of CSL Seqirus creates uncertainty regarding future funding, supply, and commercialization obligations.
Trade Secret Lawsuit Risk Lawsuit alleging trade secret misappropriation against AbbVie could result in material adverse effects on business and cash flows.

Outlook

Advance Key Clinical Programs Plans include funding Phase 2 trials for LUNAR-OTC (ARCT-810) and advancing LUNAR-CF (ARCT-032) candidate.
Require Additional Capital Expect continued losses, requiring additional equity/debt financing or partnerships to fund long-term development plans.
KOSTAIVE Regulatory Progress Evaluating FDA feedback on BLA submission for KOSTAIVE; MAA expected in UK Q1 2026.
Expect Lower Future Costs Payroll and benefits costs expected to decrease due to reduced share-based compensation expense moving forward.

Peer Comparison

Revenue (TTM)

REGENXBIO Inc.RGNX
$161.32M
+91.3%
Arcturus Therapeutics Holdings Inc.ARCT
$92.04M
-35.4%
Gossamer Bio, Inc.GOSS
$44.05M
-60.7%

Gross Margin (Latest Quarter)

Gossamer Bio, Inc.GOSS
100.0%
+0.0pp
REGENXBIO Inc.RGNX
80.7%
+31.9pp
Verastem, Inc.VSTM
73.1%
-26.8pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
SVRA$1.23B-11.9-69.1%18.1%
GOSS$778.84M-5.6-1774.7%84.2%
KALV$758.19M-4.0-195.6%2.9%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-6.5%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 5, 2026
|
EPS:-$0.87
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 12, 2025|
    Revenue: $17.15M-55.8%
    |
    EPS: $-0.49-450.0%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 11, 2025|
    Revenue: $24.51M-46.7%
    |
    EPS: $-0.34-46.9%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 12, 2025|
    Revenue: $29.38M-9.9%
    |
    EPS: $-0.52-48.0%
    Beat

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 6, 2025|
    Revenue: $138.39M-12.3%
    |
    EPS: $-3.00-167.9%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $38.82M-10.5%
    |
    EPS: $0.14-123.0%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 5, 2024|
    Revenue: $45.98M+380.7%
    |
    EPS: $-0.64-67.7%
    Beat

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 8, 2024|
    Revenue: $32.60M-59.1%
    |
    EPS: $-1.00-152.4%
    Beat

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 14, 2024|
    Revenue: $157.75M-23.3%
    |
    EPS: $-1.12-420.0%
    Miss